This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
SciBase is launching the next generation of Nevisense, Nevisense V. Nevisense by SciBase utilizes electrical impedance spectroscopy to measure how electricity flows through skin at different depths for the non-visual detection of malignant melanoma. The new platform features an updated user interface, enhanced display resolution, and an upgraded, more user-friendly touchscreen.
Panelists discuss how long-term data confirm the sustained efficacy and safety of IL-17 inhibitors in psoriasis. Secukinumab (Bissonnette, 2018; Langley, 2022) and ixekizumab (Blauvelt, 2021) show durable PASI responses over 5 years. Brodalumabs 5-year pharmacovigilance (Lebwohl, 2024) and 120-week data (Puig, 2020) support its long-term use. Bimekizumabs 4-year data (Blauvelt, 2024; Gordon, 2024) demonstrate continued efficacy, with 5-year results anticipated at AAD 2025.
Palvella Therapeutics, Inc. s QTORIN rapamycin 3.9% anhydrous gel is showing promise in the treatment of microcystic lymphatic malformations (microcystic LMs), according to a presentation at the 15th World Congress of Pediatric Dermatology in Buenos Aires, Argentina. There are no U.S. Food and Drug Administration (FDA)-approved therapies for microcystic LMs.
Sun Pharma is no longer under any court order that delays or restricts the launch of deuruxolitinib (Leqselvi) after receiving a favorable ruling from a New Jersey federal court, according to media reports. The U.S. Food and Drug Administration (FDA) approved deuruxolitinib (Leqselvi, Sun Pharma) for adults with severe alopecia areata in 2024. This is the third Janus kinase (JAK) inhibitor approved for alopecia.
You have a roster of talented stylists, a great service menu and professional products, but you've got openings in your booking software. Learn how to use video consultations to boost salon bookings and profitability.
You have a roster of talented stylists, a great service menu and professional products, but you've got openings in your booking software. Learn how to use video consultations to boost salon bookings and profitability.
Do exfoliating cleansers work? Mmm… You need cleanse and exfoliate. These steps AREN’T optional. Why not buy an exfoliating cleanser and do both at the same time? It’ll save you money and time in the evening, right? Not so fast… There are two types of cleansing exfoliants: physical and chemical. One of them doesn’t work. […] The post Do Exfoliating Cleansers Work?
An expert discusses whether the 31-gene expression profile (GEP) risk classification would change treatment guidelines and how the patients GEP risk level would influence the approach to surveillance and follow-up.
Panelists discuss how individual patient characteristics, including comorbidities, treatment history, and personal preferences, guide therapeutic decision-making for a 38-year-old woman with severe atopic dermatitis.
Jennifer Soung, MD, discusses how the biggest frustrations parents express about current treatment options for their children with AD, including limited effectiveness, side effects, and the lack of long-term solutions.
Jennifer Soung, MD, discusses how having more nonsteroidal options for long-term atopic dermatitis management is crucial, especially for younger children, to minimize potential side effects and support safer, sustained treatment.
Jennifer Soung, MD, discusses how ruxolitinib cream, if approved for use in ages 211, could become a valuable addition to the treatment landscape for pediatric atopic dermatitis by offering a non-steroidal option for managing inflammation and symptoms.
Jennifer Soung, MD, discusses how convenience and ease of use influence treatment adherence and how a new topical JAK inhibitor could enhance real-world outcomes by simplifying application and improving patient compliance.
Panelists discuss how to identify suitable patients for JAK inhibitor therapy by evaluating disease severity, medical history, risk factors, and individual treatment goals while considering contraindications and safety considerations.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
56 
Let's personalize your content